Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Inhibikase Therapeutics Inc
(NQ:
IKT
)
1.430
+0.060 (+4.38%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Inhibikase Therapeutics Inc
< Previous
1
2
3
4
5
Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 12, 2023
Via
Benzinga
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
December 11, 2023
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
December 04, 2023
Via
Benzinga
Inhibikase Therapeutics: Q3 Earnings Insights
November 14, 2023
Via
Benzinga
Earnings Preview For Inhibikase Therapeutics
November 13, 2023
Via
Benzinga
Earnings Preview: Inhibikase Therapeutics
May 12, 2023
Via
Benzinga
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
December 04, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity
November 14, 2023
Company to host conference call on Wednesday, November 15, 2023 at 8:00 a.m. ET
From
Inhibikase Therapeutics
Via
GlobeNewswire
Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023
November 07, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
FDA Removes Regulatory Overhang From Inhibikase Therapeutics Parkinson/Atrophy Program
March 08, 2023
Via
Benzinga
Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023
November 07, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment
October 16, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
October 05, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 04, 2023
Via
Benzinga
Why Cal-Maine Foods Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
October 04, 2023
Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) jumped 95.2% to $3.7280. Gaucho Group is planning to list two of its retail properties in Argentina, in San Rafael and Cordoba, for sale, priced at $2...
Via
Benzinga
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy
October 04, 2023
From
Inhibikase Therapeutics
Via
GlobeNewswire
Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
September 20, 2023
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 70.2% to $0.8937 in pre-market trading after falling 10% on Tuesday.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
September 19, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
August 25, 2023
Via
Benzinga
Why Avalo Therapeutics Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
August 18, 2023
Gainers
Via
Benzinga
Earnings Scheduled For August 14, 2023
August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.
Via
Benzinga
Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology
May 24, 2023
IKT's heavily discounted valuation provides a compelling risk/reward given the ability to establish both safety and efficacy in Parkinson’s disease let alone any progress in oncology.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
April 18, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
April 18, 2023
We're starting off the day with a look at the biggest pre-market stock movers traders will want to keep an eye on Tuesday!
Via
InvestorPlace
Shares Of Inhibikase Therapeutics Stock Decouples From NASDAQ Weakness; Jump 8% Including A/H Wednesday As Interest In Ikt-148009 Intensifies ($IKT)
March 16, 2023
Via
AB Newswire
Exposures
Product Safety
Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 14, 2023
Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a...
Via
Benzinga
Inhibikase Therapeutics Stock Turns Bullish After FDA Lifts Full Clinical Hold For Lead Candidate IkT-148009 ($IKT)
March 14, 2023
Via
AB Newswire
Exposures
Product Safety
Why Panbela Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 26, 2023
Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $2.90. MicroAlgo recently entered into securities purchase agreement for up to $3.2 million.
Via
Benzinga
Why Is Chevron (CVX) Stock Up Today?
January 26, 2023
Chevron (CVX) stock is on the rise Thursday following a new share buyback program and dividend for investors, as well as upcoming earnings.
Via
InvestorPlace
LUV Stock Alert: Southwest Reports $800 Million Loss During Holiday Mishap
January 26, 2023
Southwest Airlines (LUV) stock is falling on Thursday following a massive $800 million hit to its net income in Q4 2022.
Via
InvestorPlace
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.